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The levels of serum chemokines in patients with Behçet’s disease
İbrahim KÖKÇAM1, Dilara TURGUT2, Nafiye Fulya İLHAN3, Demet ÇİÇEK1

Aim: As chemokines are involved in the regulation of immune responses and inflammatory reactions, this study aimed
to investigate the serum levels of some chemokines to determine whether they play roles in the pathogenesis of Behçet’s
disease (BD).
Materials and methods: The study comprised 64 cases, allocated to active or inactive patient groups. The levels of serum
macrophage inflammatory protein-1α (MIP-1α), epithelial neutrophil-activating protein-78 (ENA-78), and neutrophilactivating peptide-2 (NAP-2) were measured.
Results: The serum levels of MIP-1α and ENA-78 were statistically higher in BD patients than controls (P = 0.032 and
P = 0.023, respectively). However, NAP-2 levels did not differ significantly between patients and controls (P > 0.05). A
significantly higher mean serum level of ENA-78 was found in patients with active disease compared to patients with
inactive disease and controls (P = 0.029 and P = 0.003, respectively). However, mean serum MIP-1α and NAP-2 levels
did not differ significantly between active and inactive patients (P > 0.05).
Conclusion: In this study, there was a significant elevation of MIP-1α and ENA-78 supporting the role of neutrophil
hyperactivity in BD. However, because chemokines insert their effects in the microenvironment and serum concentrations
reflect a developing inflammatory process indirectly, we suggest that more comprehensive studies are needed to reveal
the role of chemokines in the pathogenesis of the disease.
Key words: Behçet’s disease, pathogenesis, macrophage inflammatory protein-1α, epithelial neutrophil-activating
protein-78, neutrophil-activating peptide-2

Introduction
Behçet’s disease (BD) is a chronic inflammatory
disease of unknown etiology, accompanied by
vasculitis in various organs, and active leukocytes
play a pivotal role in its pathogenesis. Prominent
neutrophil infiltration is present in typical BD
lesions (1,2). Immunological mechanisms occupy
an important place in the pathogenesis of BD.
Therefore, studies investigating the role of immune
mechanisms in the pathogenesis of the disease have
been increasing recently (3-6).

Chemokines are chemotactic factors for
leukocytes. They mediate the migration and activation
of leukocytes at sites of inflammation. They also have
important roles in hematopoiesis, angiogenesis,
tumor growth, and various autoimmune diseases,
including rheumatoid arthritis, systemic sclerosis, and
BD (6). The CXC chemokines predominantly activate
neutrophils, while the CC chemokines generally
activate monocytes, lymphocytes, basophils, and
eosinophils. Macrophage inflammatory protein-1α
(MIP-1α) (CCL3) is a member of the CC chemokine
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subfamily. This molecule plays an important role in
inflammation. MIP-1α activates inflammatory cells
and acts as a regulator in growth and differentiation
of various cells. It also exerts a chemotactic effect for
monocytes and T cells (7,8). Epithelial neutrophilactivating protein-78 (ENA-78) (CXCL5) is a
member of the CXC chemokine family. Its structural
features and biological activities are similar to
those of interleukin (IL)-8 (9-11). Neutrophilactivating peptide-2 (NAP-2) (CXCL7) also belongs
to the CXC chemokine family and is responsible
for the chemotaxis and activation of neutrophils.
It was reported that Th1 activity increases in BD,
particularly in active BD (7,12). As chemokines are
involved in the regulation of immune responses and
inflammatory reactions, we investigated whether
they may play a role in the pathogenesis of BD.
Materials and methods
Sixty-four Turkish patients with BD and 24 matched
healthy controls were enrolled in this study. Patients
were diagnosed according to the International
Study Group (ISG) diagnostic criteria for BD at the
Dermatology Clinic of the Firat University School
of Medicine (13). Patients selected had received no
antiinflammatory therapy in the last month, taking
into consideration that it can suppress chemokines
response. However, blood samples were obtained
in pretreatment period from patients with systemic
involvement who needed immunosuppressive
therapy. The patients were grouped as active or
inactive. At the time of the study, the patients who
met at least one criterion of the ISG for BD were
considered to be in the active stage of the disease.
Patients who had been free of lesions for the previous
30 days or more were accepted as having inactive
BD. Necessary permission concerning the study
was obtained from the local ethics committee. Each
patient was informed in detail about the study and
those who agreed to be included were asked to sign
an informed consent form.
Preparation of serum samples
Venous blood samples were taken from the antecubital
vein for biochemical assays. These samples were
centrifuged at 4000 rpm for 5 min with a Hettich
Universal 32 centrifuge (Germany). The sera were
separated and kept at –80 °C until the day of analysis.
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Chemokine investigation
A human MIP-1α ELISA kit from BioSource
International Inc. (USA) was used to determine
MIP-1α. A RayBio Human NAP-2 ELISA kit from
RayBiotech Inc. (USA) was used to determine NAP2. A human ENA-78 Quantikine® ELISA kit from
R&D Systems Inc. (USA) was used to determine
ENA-78. Analyses were performed in immunology
laboratories with a Triturus Grifols (Spain) fully
automatic ELISA analyzer by using controls and
calibrations in accordance with the manufacturer’s
recommended study protocols. For each chemokine,
all sera were tested in the same plate following the
same study procedure. Eight wells per plate were
used for calibrators. The results were read on a
spectrophotometer at 450 nm. The results of the
study were calculated based on their optic densities
by drawing curves from one point to another.
Statistical analysis
SPSS 11.0 was used for data analysis (SPSS Inc., USA).
All values are given as mean ± standard deviation.
The chi-square test was used for sex distribution
among the groups, while the Mann-Whitney U test
was used for comparing the data between groups.
Additionally, the Kruskal-Wallis test was used for
triple comparison of the data from active and inactive
patients and controls. The Mann-Whitney U test was
used for paired comparison of groups in statistically
significant values. P < 0.05 was accepted as indicating
statistical significance.
Results
A total of 64 BD patients (27 males, 37 females),
including 46 active patients and 24 healthy controls
(10 males, 14 females), were enrolled in the study.
The mean age of the BD group was 36.81 ± 11.65
years (age range: 17- 66 years) and that of the control
group was 33.88 ± 9.51 years (age range: 25-28 years).
There were no statistically significant differences in
age and sex distribution between the groups (P >
0.05). The distribution of present symptoms and
findings together with the demographic features of
the patients included in the study are listed in Tables
1 and 2.
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Table 1. The demographic features of the patients included in the study.
Patient group

Control group

Number of cases (n)

64

24

Number of active patients (n)

46

P

Age (years)

36.81 ± 11.65

33.88 ± 9.51

>0.05

Sex (M/F)

27/37

10/14

>0.05

Duration of the disease (years)
Active patients

5.06 ± 6.31

Inactive patients

6.63 ± 7.68

Table 2. Distribution of the symptoms and findings in Behçet’s disease.
Symptoms and findings

Number of cases (n)

OA

30

GU

12

EI

6

Arthralgia

28

Arthritis

16

AL

16

EN

11

Thrombophlebitis

4

GSI

1

NI

5

PTP

8

OA: Oral aphthous ulcer, GU: genital ulcer, EI: eye involvement, AL: acneform lesions,
EN: erythema nodosum, GSI: gastrointestinal system involvement, NI: neurological
involvement, PTP: pathergy test positivity.

Significantly higher mean serum levels of MIP1α and ENA-78 were found in the patient group
compared to the controls (P = 0.032 and P = 0.023,
respectively). NAP-2 levels did not differ significantly
between patients and controls (P > 0.05). The mean
serum levels of the 3 chemokines studied are listed
in Table 3. A significantly higher mean serum level
of ENA-78 was found in patients with active disease
compared to patients with inactive disease and
controls (P = 0.029 and P = 0.003, respectively).
However, mean serum MIP-1α and NAP-2 levels did
not differ significantly between active and inactive
patients (P > 0.05).

Discussion
The etiopathogenesis of BD has not yet been clarified,
but it might involve immune dysfunction (6).
Chemokines enable the firm adhesion of leukocytes
to endothelial cells, migration to interstitial tissue,
and direct leukocyte activation (9). Additionally,
chemokines play a role in attracting cell groups to
inflammation sites at different times. Neutrophils are
suggested to have a primary role in BD lesions, such
as in the pathergy phenomenon and acne-like lesions
(6). MIP-1α is bound to the CCR5 receptor expressed
by Th1 and also to the CCR1 receptor expressed by
1107
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Table 3. Mean sera levels of the 3 chemokines studied.
Patient group (n = 64)
Active patient group (n = 46)
MIP-1α (pg/mL)

ENA-78 (pg/mL)

NAP-2 (pg/mL)

Control group

Inactive patient group (n = 18)

96.10 ± 15.21a
95.23 ± 13.93

98.32 ± 18.33

1274.80 ± 686.45b
1373.17 ± 651.90c,d

1023.41 ± 726.79

470.13 ± 47.85
470.26 ± 48.65

469.81 ± 47.13

(n = 24)
88.92 ± 5.32

926.12 ± 558.33

492.05 ± 54.12

a

: vs. control group, P = 0.032.
: vs. control group, P = 0.023.
c
: vs. control group, P = 0.003.
d
: vs. inactive group, P = 0.029.
b

both Th1 and Th2, which indicates that MIP-1α
particularly stimulates Th1 activity. It was reported
that Th1 activity increases in BD, particularly in
active patients (14). Similar to our results, Ozer et al.
reported higher MIP-1α and MCP-1 levels in active
BD patients than controls (12). We think that these
chemokines have an important role in leukocyte
activation and migration, and in addition to this
role, they have an effect on Th1 polarization, which
is cited in the BD pathogenesis. All of these increase
Th1 activities and inflammatory cell accumulation
in the inflammatory area. MIP-1 was found to be
increased in the serum samples in other studies
(12,15). Saruhan-Direskeneli et al. and Miyagishi et
al., in 2 different studies, determined high MIP-1α
levels in the cerebrospinal fluid in BD patients with
neurological involvement (14,16).
In our patients, serum MIP-1α levels were
significantly higher than in the controls, similar
to the previously mentioned studies. However,
there was no significant difference in MIP-1α levels
between active and inactive patients. Unfortunately,
our patients were not grouped by neurological or
other organ involvement, and this patient group was
too limited to interpret these results according to
diagnostic criteria or to shed light upon the specific
etiopathogenesis of BD.
ENA-78 is a potent neutrophil activator with
similar biological properties as demonstrated for IL1108

8, NAP-2, and growth-related oncogenes-α (17). IL-8
mRNA expression was more prominent in patients
with active BD than in patients with inactive disease
(18). In a study conducted by Sugiyama et al., ENA78 and interferon gamma-inducible protein (IP)-10
levels in the bronchoalveolar lavage (BAL) fluid and
sera of 41 patients in various phases of pulmonary
sarcoidosis were measured. They reported that IP10 was increased in both serum and BAL fluid in
the healthy control group in comparison to BD
patients, and ENA-78 was increased only in stage
3 sarcoidosis. They suggested that the increase in
ENA-78 in stage 3, where fibrosis occurred, might
be due to its fibrogenetic function (19). Olszyna et
al. researched whether chemokines and ENA-78
played a role in infections other than chronic diseases
such as sarcoidosis. They detected that chemokines
(including ENA-78) were significantly increased
in urine samples in urosepsis patients, but not in
plasma samples. As a result, they concluded that
CXC chemokines were produced primarily from
the urinary channel in patients with urosepsis, and
thus neutrophils gathered in the urinary site (20).
Z’Graggen et al. demonstrated that ENA-78 mRNA
gene expression increased in intestinal epithelial cells
of patients with Crohn’s disease and ulcerative colitis
(21). Those data indicate that ENA-78 might play a
pivotal role in patients with BD. We could not find
other previous studies investigating serum levels of
ENA-78 in patients with BD for comparison with our
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results. In our study, we detected significantly higher
ENA-78 serum levels in BD, particularly in the active
patient group, when compared to the control group.
This can be attributed to neutrophils gathering at
inflammatory sites and exacerbations of Behçet’s
vasculitis and inflammation in different sites of the
body. For more specific results, different body fluids
should be investigated in different BD involvements.

other results, NAP-2 can be an effector chemokine,
especially for thrombus formation; however,
thrombocytes are not the primary effector cells in
BD and the definitive pathogenetic mechanism of
thrombotic tendency of BD is not fully elucidated.
None of our patients had thrombotic tendency and
we were unable to determine any increase in NAP-2
serum levels.

In our study, we aimed to investigate NAP-2,
which belongs to the CXC chemokine family and is
responsible for neutrophil chemotaxis and activation,
and particularly its role in the pathogenesis of BD.
Since NAP-2 is primarily a thrombocyte-derived
chemokine, most studies are focused on the diseases
in which thrombocytes play a role in the pathogenesis
(22). NAP-2 was investigated in the pathogenesis
of coronary artery disease. The authors found both
high plasma NAP-2 level and increased CXCR2
receptors in monocytes with stable and particularly
unstable angina in comparison to the control group.
Thrombocyte-derived NAP-2 especially enhanced the
expression of chemokines and adhesion molecules
in endothelial cells (23). According to previous
studies, NAP-2 is formed by platelet basic protein
and connective tissue-activating peptide III released
by active thrombocytes, and it leads to neutrophil
gathering in thrombocyte clumps (24). According to

In conclusion, in the current study, in which the
levels of some chemokines that are known to play
a role in neutrophil activity were investigated, the
significant elevation of MIP-1α and ENA-78 supports
the role of neutrophil hyperactivity in this disease.
However, chemokines insert their effects in the
microenvironment and serum concentrations reflect
a developing inflammatory process indirectly. Thus,
for clearer results, tissue levels of these chemokines
should be determined, as well as the relation of disease
activation and the correlation of therapy response.
We suggest that more comprehensive studies are
needed in order to reveal the role of chemokines.
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